Imperial College London
Portrait Picture

ProfessorVictoriaCornelius

Faculty of Medicine, School of Public Health

Professor in Medical Statistics and Trials Methodology
 
 
 
//

Contact

 

+44 (0)20 7594 1218v.cornelius

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

111Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Chan:2020:10.1001/jamapediatrics.2019.4476,
author = {Chan, S and Cornelius, V and Cro, S and Harper, JI and Lack, G},
doi = {10.1001/jamapediatrics.2019.4476},
journal = {JAMA Pediatrics},
pages = {29--37},
title = {Treatment effect of omalizumab on severe pediatric atopic dermatitis: The ADAPT randomized clinical trial},
url = {http://dx.doi.org/10.1001/jamapediatrics.2019.4476},
volume = {174},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Importance: Systemic treatments for severe childhood atopic dermatitis have limited evidence and/or are unlicensed. Despite the efficacy of anti-IgE medication (omalizumab) in the treatment of atopy, no large randomized studies in childhood atopic dermatitis have been published. Objective: To determine the effectiveness of omalizumab in treating severe atopic dermatitis in children. Design, Setting, and Participants: The Atopic Dermatitis Anti-IgE Pediatric Trial (ADAPT) was a 24-week single-center, double-blind, placebo-controlled randomized clinical trial with a 24-week follow-up. Conducted from November 20, 2014, to August 31, 2017, at Guy's and St Thomas' Hospital NHS Foundation Trust and King's College London in the United Kingdom, this trial recruited participants after a screening visit. Eligible participants (n = 62) were aged 4 to 19 years and had severe eczema (with objective Scoring Atopic Dermatitis [SCORAD] index >40) that was unresponsive to optimum therapy. Statistical analysis was conducted using the intention-to-treat principle. Interventions: Subcutaneous omalizumab or placebo for 24 weeks. The drug manufacturer's dosing tables were used to determine the dosage based on total IgE (30-1500 IU/mL) and body weight (in kilograms) at randomization. Main Outcomes and Measures: Objective SCORAD index after 24 weeks of treatment. Results: In total, 62 children (mean [SD] age, 10.3 [4.2] years; 32 (52%) were male) were randomized to either omalizumab (n = 30) or placebo (n = 32). Five participants withdrew from treatment (4 [13%] from the placebo group, and 1 [3%] from the omalizumab group). Follow-up attendance was 97% at week 24 and 98% at week 48. After adjustment for baseline objective SCORAD index, age, and IgE level, the mean difference in objective SCORAD index improvement between groups at week 24 was -6.9 (95% CI, -12.2 to -1.5; P = .01), significantly favoring omalizumab therapy and reflec
AU  - Chan,S
AU  - Cornelius,V
AU  - Cro,S
AU  - Harper,JI
AU  - Lack,G
DO  - 10.1001/jamapediatrics.2019.4476
EP  - 37
PY  - 2020///
SN  - 2168-6203
SP  - 29
TI  - Treatment effect of omalizumab on severe pediatric atopic dermatitis: The ADAPT randomized clinical trial
T2  - JAMA Pediatrics
UR  - http://dx.doi.org/10.1001/jamapediatrics.2019.4476
UR  - https://www.ncbi.nlm.nih.gov/pubmed/31764962
UR  - https://jamanetwork.com/journals/jamapediatrics/fullarticle/2755655
UR  - http://hdl.handle.net/10044/1/75368
VL  - 174
ER  -
Download